IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Darren MAGDA et al.

Group Art Unit: 162

Serial Number: 10/552,696

Examiner: Not Yet Assigned

Filing Date:

10/06/2005

CONFIRMATION NO: 3832

Title:

Sapphyrins and Uses Thereof

Certificate of Electronic Filing

I hereby certify that the attached Information Disclosure Statement and all marked attachments are being deposited by Electronic Filling on November \$\frac{9}{2}\$. 2006 by using the EFS — Web patent filling system and addressed to: Commissioner for Patents, P.O. Box 1450. Alexandris, VA 22313-1450.

By: Ann Lygas

Date: November 3 9 2006

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached forms PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached forms PTO/SBOS in accordance with MPEP 8609.

Applicants reserve the right to establish the patentiability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.					
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);		
			OR		
		(2)	It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;		
			OR		
	\boxtimes	(3)	It is being filed before the mailing of a first Office action on the merits;		
			OR		
		(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.		
B.	B. 37 CFR \$1.97(c). Although this Information Disclosure Statement is being filed after the perspecified in 37 CFR \$1.97(b), above, it is filed before the mailing date of the earlier of (1) a 1 office action under \$1.113, (2) a notice of allowance under \$1.311, or (3) an action that other closes prosecution on the merits, this Information Disclosure Statement should be considered been it is accompanied by one of				
		a state	ment as specified in §1.97(e) provided concurrently herewith;		
			OR		
			of \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the ent of other papers filed together with this statement.		
C.	☐ 37 CFR §1.97(d). Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311 it is being filed before payment of the issue fee and should be considered because it is accompanied by:				
		i. as	tatement as specified in §1.97(e);		
			- AND		
			ee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included the payment of other papers filed together with this Statement.		
D.	☐ 37 CFI	R §1.97	(e). Statement.		
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);		
			AND/OR		
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);		
			- AND/OR -		
	\boxtimes		y of a dated communication from a foreign patent office clearly showing that the		

provided for under MPEP 609.04(b) V.

the communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as

E.	disclosure application prior to the requirement	tenent (order ') C.F.R. § 1.704(a). Each usen of innormation contained in the innormation true statement was first cited in a communication from a foreign patient office in a counterpart tion that was received by an individual designated in § 1.56(c) not more than mailto:received by an individual designated in § 1.56(c) not more than mailto:received by an individual designated in § 1.56(c) not more than <a href="mailto:received by an individual designated by 1.55(c) not more than the individual designated by the filling of this information disclosure statement of the part term
fillinant(s) delay. The property of the individual designated in the property of the period of adjustment of the patent term
placet(s).</th></tr><tr><td>F.</td><td>37 CFI</td><td><math>R \le 1.98(a)(2)</math>. The content of the Information Disclosure Statement is as follows:</td></tr><tr><td></td><td></td><td>Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.</td></tr><tr><td></td><td></td><td> OR</td></tr><tr><td></td><td><math>\boxtimes</math></td><td>Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached <math display=" inline"="">{\tt FormPTO/SB/08} are NOT enclosed.				
		- AND/OR				
	\boxtimes	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR \S 1.98 (a)(2).				
		AND/OR				
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR $\S1.98(a)(2)(iii)$.				
G.	☐ 37 CF. references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or				
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.				
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.				
		OR				
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:				
		Pursuant to 37 CFR $\S1.98(a)(3)(ii)$, a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.				
H.		$R \ \$ 1.98(d)$. Copies of patents, publications and pending U.S. patent applications, or other a specified in 37 C.F.R. $\$ 1.98(a)$ are not provided herewith because:				
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.				
		Application in which the information was submitted:				
		Information Disclosure Statement(s) filed on:				
	_	AND				
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.				

 \(\frac{\text{Fee Authorization}}{\text{constraint}} \)
 (The Commissioner is hereby authorized to charge the above-referenced fees of \$9.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Decket No. 2592-2719-831).

Respectfully submitted,

Reg. No. 47,664

WILSON SONSINI GOODRICH & ROSATI

Dated: 11 74 7000 By. Michael J. Hostetler, Ph.D.

-4-

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971

PTO/SB/98 (97/95)

Approved for use through 07/31/2006. OMB 98(07/05)

				Complete if Known		
Substitute for form 1449/PTO				Application Number	10/552,696	
INFORMATION DISCLOSURE			LOSURE	Filing Date	10/06/2005	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Darren MAGDA et al.	
				Art Unit	1623	
				Examiner Name	Not Yet Assigned	
Sheet	1	Of	1	Attorney Docket Number	25922-710.831	

Examiner Initials*	No.	Document Number Number Kind Code ² (§' known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, W Relevant Passages or Rele Figures Appear		
	1.	US-5,543,514	08-06-1996	Sessler et al.			
		NON PATENT	LITERATUR	E DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, eity and/or country where publisher articles.					
	2.	MAIYA et al., "In Vitro Photodynamic Activity of Diprotonated Sapphyrin: A 22-π- Electron Pentapyrrolic Porphyrin-like Macrocycle," J. Phys. Chem. 94:3597-3601 (1990)					

U.S. PATENT DOCUMENTS

Examiner	Date	
Signature	Considered	

"A ALESSA", the of contracts contained, where we are more in the contract with PEP TO The part has being described from a contracted in their tray of the contract with the co